All In Biotech

Drug Trial Radar · NCT03049852

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium

Last checked: Nov 19, 2026Latest source record: Feb 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Apr 15, 2017

Primary completion

Apr 30, 2018

Study completion Apr 30, 2018

Sponsor

Lead sponsor
Cloudbreak Therapeutics, LLCIndustry
Sponsor type
Industry
First posted
Feb 10, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)

Conditions

  • Pterygium

Interventions

  • CBT-001 single doseDrug

    One drop in the study administered one time

  • VehicleDrug

    One drop in the study administered three times daily (TID) for 4 weeks

  • CBT-001 Multi-doseDrug

    One drop in the study administered three times daily (TID) for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading ScaleTime frame: Change from baseline at 4 weeks
  2. Ocular and General Safety and TolerabilityTime frame: One day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harvard Eye Associates

    Laguna Beach, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.